Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor Licenses Antibody Optimization Technology
Xencor Licenses Antibody Optimization Technology Monrovia, Calif. – November 30, 2009 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology
View HTML
Toggle Summary Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board
Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board Monrovia, CA—December 7, 2009 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today the appointment of Bruce Carter, Ph.D.
View HTML
Toggle Summary Xencor Receives Milestone Payment from Pfizer Under Antibody Technology License Agreement
Xencor Receives Milestone Payment from Pfizer Under Antibody Technology License Agreement Monrovia, CA—December 16, 2009 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today that the Company received a milestone
View HTML
Toggle Summary Data Published in Nature Biotechnology Shows Fc Engineering Improves Antibody Efficacy and Convenience
Data Published in Nature Biotechnology Shows Fc Engineering Improves Antibody Efficacy and Convenience Monrovia, Calif. – January 19, 2010 – A Nature Biotechnology article published online January 17 reveals that Xencor Inc.'s proprietary Fc engineering extends the half-life of antibodies
View HTML
Toggle Summary Xencor Appoints Edgardo Baracchini, Ph.D., to Chief Business Officer
Xencor Appoints Edgardo Baracchini, Ph.D., to Chief Business Officer Monrovia, Calif. – February 9, 2010 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today the appointment of Edgardo Baracchini, Ph.D., to chief
View HTML
Toggle Summary MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program
MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program Martinsried/Munich, Germany, and Monrovia, Calif. – June 28, 2010 – MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) and US-based biopharmaceutical company Xencor, Inc., announced today the
View HTML
Toggle Summary Xencor Receives Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement
Xencor Receives Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement Monrovia, CA—October 12, 2010 – Xencor, Inc. announced today that the Company received a milestone payment from Boehringer Ingelheim. The payment was triggered by the regulatory
View HTML
Toggle Summary Xencor and MorphoSys Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia
Xencor and MorphoSys Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia Monrovia, Calif. – December 2, 2010 – Xencor, Inc. and MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208),
View HTML
Toggle Summary Amgen And Xencor Enter Option Deal To Co-develop Xencor's Novel Antibody For Autoimmune Diseases
Amgen And Xencor Enter Option Deal To Co-develop Xencor's Novel Antibody For Autoimmune Diseases Thousand Oaks, Calif. and Monrovia, Calif. – (Jan. 6, 2011) – Amgen (NASDAQ: AMGN) and Xencor, Inc. announced today that they will collaborate to develop XmAb®5871, an Fc- engineered
View HTML
Toggle Summary Xencor's Fc Engineered Antibody Suppresses Autoimmunity in Preclinical Systemic Lupus Erythematosus Models; Data Published in Journal of Immunology
Monrovia, Calif. – March 9, 2011 – Xencor, Inc. announced positive results from preclinical studies of XmAb®5871, a humanized monoclonal antibody that dually targets CD19 and CD32b (FcyRIIb) for the treatment of autoimmune diseases, demonstrating that XmAb5871 is a potent suppressor of B cell
View HTML